Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 45


Diagnostic dilemmas in HLH: Can T-cell phenotyping help?

Marsh RA.

Eur J Immunol. 2017 Feb;47(2):240-243. doi: 10.1002/eji.201646841.


Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.

Marsh RA, Fukuda T, Emoto C, Neumeier L, Khandelwal P, Chandra S, Teusink-Cross A, Vinks AA, Mehta PA.

Biol Blood Marrow Transplant. 2017 Jan 12. pii: S1083-8791(17)30196-9. doi: 10.1016/j.bbmt.2017.01.071. [Epub ahead of print]


Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.

Marsh RA, Jordan MB, Talano JA, Nichols KE, Kumar A, Naqvi A, Vaiselbuh SR; Histiocyte Society Salvage Therapy Working Group..

Pediatr Blood Cancer. 2016 Oct 27. doi: 10.1002/pbc.26308. [Epub ahead of print] Review.


A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.

Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE, El-Bietar J, Chandra S, Davies SM, Bleesing JJ, Jordan MB, Mehta PA, Jodele S, Grimley MS, Kumar A, Myers KC, Marsh RA.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2220-2225. doi: 10.1016/j.bbmt.2016.09.016.


Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant.

Chandrakasan S, Marsh RA, Uzel G, Holland SM, Shah KN, Bleesing J.

J Allergy Clin Immunol. 2016 Oct 12. pii: S0091-6749(16)31123-X. doi: 10.1016/j.jaci.2016.08.039. [Epub ahead of print] No abstract available.


A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.

Khandelwal P, Fukuda T, Mizuno K, Teusink-Cross A, Mehta PA, Marsh RA, Kashuba AD, Vinks AA, Davies SM.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1829-35. doi: 10.1016/j.bbmt.2016.08.001.


The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis.

Hartz B, Marsh R, Rao K, Henter JI, Jordan M, Filipovich L, Bader P, Beier R, Burkhardt B, Meisel R, Schulz A, Winkler B, Albert MH, Greil J, Karasu G, Woessmann W, Corbacioglu S, Gruhn B, Holter W, Kühl JS, Lang P, Seidel MG, Veys P, Löfstedt A, Ammann S, Ehl S, Janka G, Müller I, Lehmberg K.

Blood. 2016 Jun 23;127(25):3281-90. doi: 10.1182/blood-2015-12-684498.


A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.

Nelson AS, Marsh RA, Myers KC, Davies SM, Jodele S, O'Brien TA, Mehta PA.

Biol Blood Marrow Transplant. 2016 May;22(5):884-8. doi: 10.1016/j.bbmt.2016.01.026.


Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients.

Khandelwal P, Mellor-Heineke S, Rehman N, Lane A, Smiley K, Villanueva J, Marsh RA, Grimley MS, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2016 Apr;22(4):690-7. doi: 10.1016/j.bbmt.2015.12.016.


Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.

Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, Filipovich AH.

Blood. 2016 Jan 28;127(4):503-12. doi: 10.1182/blood-2015-07-659672.


A challenging undertaking: Stem cell transplantation for immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome.

Kucuk ZY, Bleesing JJ, Marsh R, Zhang K, Davies S, Filipovich AH.

J Allergy Clin Immunol. 2016 Mar;137(3):953-5.e4. doi: 10.1016/j.jaci.2015.09.030. No abstract available.


Accuracy of flow cytometric perforin screening for detecting patients with FHL due to PRF1 mutations.

Abdalgani M, Filipovich AH, Choo S, Zhang K, Gifford C, Villanueva J, Bleesing JJ, Marsh RA.

Blood. 2015 Oct 8;126(15):1858-60. doi: 10.1182/blood-2015-06-648659. No abstract available.


AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.

Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, Zhang Y, Liu Z, Fritz JM, Marsh R, Husami A, Kissell D, Nortman S, Chaturvedi V, Haines H, Young LR, Mo J, Filipovich AH, Bleesing JJ, Mustillo P, Stephens M, Rueda CM, Chougnet CA, Hoebe K, McElwee J, Hughes JD, Karakoc-Aydiner E, Matthews HF, Price S, Su HC, Rao VK, Lenardo MJ, Jordan MB.

Science. 2015 Jul 24;349(6246):436-40. doi: 10.1126/science.aaa1663.


Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease.

Khandelwal P, Lane A, Chaturvedi V, Owsley E, Davies SM, Marmer D, Filipovich AH, Jordan MB, Marsh RA.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1215-22. doi: 10.1016/j.bbmt.2015.04.010.


Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009.


Hemophagocytic lymphohistiocytosis in a female patient due to a heterozygous XIAP mutation and skewed X chromosome inactivation.

Holle JR, Marsh RA, Holdcroft AM, Davies SM, Wang L, Zhang K, Jordan MB.

Pediatr Blood Cancer. 2015 Jul;62(7):1288-90. doi: 10.1002/pbc.25483.


Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.

Haines HL, Bleesing JJ, Davies SM, Hornung L, Jordan MB, Marsh RA, Filipovich AH.

Biol Blood Marrow Transplant. 2015 Feb;21(2):288-92. doi: 10.1016/j.bbmt.2014.10.010.


SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.

Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B.

Oncotarget. 2014 Oct 30;5(20):9703-9.


An in vitro skin penetration model for compromised skin: estimating penetration of polyethylene glycol [¹⁴C]-PEG-7 phosphate.

Dey S, Rothe H, Page L, O'Connor R, Farahmand S, Toner F, Marsh R, Wehmeyer K, Zhou S.

Skin Pharmacol Physiol. 2015;28(1):12-21. doi: 10.1159/000362284.

Items per page

Supplemental Content

Loading ...
Support Center